1
|
Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O’Connell RJ, Carfi A, Barnett SW. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLoS One 2018; 13:e0194266. [PMID: 29698406 PMCID: PMC5919662 DOI: 10.1371/journal.pone.0194266] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 02/28/2018] [Indexed: 01/23/2023] Open
Abstract
The RV144 Phase III clinical trial with ALVAC-HIV prime and AIDSVAX B/E subtypes CRF01_AE (A244) and B (MN) gp120 boost vaccine regime in Thailand provided a foundation for the future development of improved vaccine strategies that may afford protection against the human immunodeficiency virus type 1 (HIV-1). Results from this trial showed that immune responses directed against specific regions V1V2 of the viral envelope (Env) glycoprotein gp120 of HIV-1, were inversely correlated to the risk of HIV-1 infection. Due to the low production of gp120 proteins in CHO cells (2–20 mg/L), cleavage sites in V1V2 loops (A244) and V3 loop (MN) causing heterogeneous antigen products, it was an urgent need to generate CHO cells harboring A244 gp120 with high production yields and an additional, homogenous and uncleaved subtype B gp120 protein to replace MN used in RV144 for the future clinical trials. Here we describe the generation of Chinese Hamster Ovary (CHO) cell lines stably expressing vaccine HIV-1 Env antigens for these purposes: one expressing an HIV-1 subtype CRF01_AE A244 Env gp120 protein (A244.AE) and one expressing an HIV-1 subtype B 6240 Env gp120 protein (6240.B) suitable for possible future manufacturing of Phase I clinical trial materials with cell culture expression levels of over 100 mg/L. The antigenic profiles of the molecules were elucidated by comprehensive approaches including analysis with a panel of well-characterized monoclonal antibodies recognizing critical epitopes using Biacore and ELISA, and glycosylation analysis by mass spectrometry, which confirmed previously identified glycosylation sites and revealed unknown sites of O-linked and N-linked glycosylations at non-consensus motifs. Overall, the vaccines given with MF59 adjuvant induced higher and more rapid antibody (Ab) responses as well as higher Ab avidity than groups given with aluminum hydroxide. Also, bivalent proteins (A244.AE and 6240.B) formulated with MF59 elicited distinct V2-specific Abs to the epitope previously shown to correlate with decreased risk of HIV-1 infection in the RV144 trial. All together, these results provide critical information allowing the consideration of these candidate gp120 proteins for future clinical evaluations in combination with a potent adjuvant.
Collapse
Affiliation(s)
- Yingxia Wen
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Hung V. Trinh
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
- Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, United States of America
| | | | | | | | | | - Priyanka Ramesh
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Yide Sun
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Frank Situ
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | | | - Christopher Hamlin
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
- Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, United States of America
| | - Sayali Onkar
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
- Henry Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, United States of America
| | - Sai Tian
- GSK, Rockville, MD, United States of America
| | - Susan Hilt
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Padma Malyala
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Rushit Lodaya
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Ning Li
- GSK, Rockville, MD, United States of America
| | - Gillis Otten
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Giuseppe Palladino
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | | | - Yukti Aggarwal
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Celia LaBranche
- Department of Surgery, Duke University Medical Center, Durham, NC, United States of America
| | - Ryan Duffy
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States of America
| | - Xiaoying Shen
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States of America
| | - Georgia D. Tomaras
- Department of Surgery, Duke University Medical Center, Durham, NC, United States of America
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States of America
| | - David C. Montefiori
- Department of Surgery, Duke University Medical Center, Durham, NC, United States of America
| | - William Fulp
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Raphael Gottardo
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Brian Burke
- Novartis Vaccines and Diagnostics, Cambridge, MA, United States of America
| | - Jeffrey B. Ulmer
- GSK, Rockville, MD, United States of America
- * E-mail: (SWB); (AC); (JBU)
| | - Susan Zolla-Pazner
- Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Hua-Xin Liao
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States of America
- Biomedine Institute, College of Life Science, Jinan University, Guangzhou, China
| | - Barton F. Haynes
- Duke Human Vaccine Institute, Duke University, Durham, NC, United States of America
| | - Nelson L. Michael
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
| | - Jerome H. Kim
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
| | - Mangala Rao
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
| | - Robert J. O’Connell
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America
- Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
| | - Andrea Carfi
- GSK, Rockville, MD, United States of America
- * E-mail: (SWB); (AC); (JBU)
| | - Susan W. Barnett
- GSK, Rockville, MD, United States of America
- * E-mail: (SWB); (AC); (JBU)
| |
Collapse
|
2
|
Lu L, An Y, Zou J, Gu L, Zhao Z, Zhang X, Li C, Kurihara C, Hokari R, Itakura J, Kurosaki M, Izumi N, Fu Y, Nakano T, Kato T, Negro F, Chen G. The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012. Virology 2015; 485:431-8. [PMID: 26343863 DOI: 10.1016/j.virol.2015.08.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 07/29/2015] [Accepted: 08/10/2015] [Indexed: 02/06/2023]
Abstract
UNLABELLED An HCV outbreak occurred in 2012 in China, affecting hundreds of patients. We characterized HCV subtype 2a and 6a sequences from 60 and 102 patients, respectively, and co-analyzed them with 82 local controls and 103 calibrating references. The close grouping of the patients׳ sequences contrasted sharply with the diversity of local controls. Scaled by the calibrating references, the emergence of patients׳ isolates was estimated at 2-5 years before sampling. In contrast, the controls intermingled with the calibrating references that were much older. For both subtypes, the major and minor clusters could be defined, with the closeness to indicate linked transmission. CONCLUSION HCV sequences from the study patients grouped into three subtype 2a and two subtype 6a clusters, in addition to three 6a solitary branches, representing descendants of eight earlier strains that were distinct and otherwise sporadic. Due to iatrogenic transmission through reusing needles, five strains were highly selected and preferentially spread.
Collapse
Affiliation(s)
- Ling Lu
- Laboratory for Hepatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; The Center for Viral Oncology, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States of America.
| | - Yuling An
- Department of Liver Transplantation, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Ji Zou
- Laboratory for Hepatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Lin Gu
- Laboratory for Hepatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Zhixin Zhao
- Laboratory for Hepatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Xiaohong Zhang
- Laboratory for Hepatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Chunhua Li
- The Center for Viral Oncology, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States of America
| | - Chie Kurihara
- Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Ryota Hokari
- Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
| | - Jun Itakura
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Masayuki Kurosaki
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Namiki Izumi
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Yongshui Fu
- Guangzhou Blood Center, Guangzhou, Guangdong, China
| | - Tatsunori Nakano
- Department of Internal Medicine, Fujita Health University, Nanakuri Sanatorium, Tsu, Mie, Japan
| | - Takanobu Kato
- Department of Virology II, National Institute of Infectious Diseases, Shinjyuku, Tokyo, Japan
| | - Francesco Negro
- Divisions of Gastroenterology and Hepatology and of Clinical pathology, University, Hospitals, Geneva, Switzerland
| | - Guihua Chen
- Department of Liver Transplantation, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
| |
Collapse
|
5
|
Wang B, Dwyer DE, Chew CB, Kol C, He ZP, Joshi H, Steain MC, Cunningham AL, Saksena NK. Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification. J Virol Methods 2009; 161:128-35. [PMID: 19523982 DOI: 10.1016/j.jviromet.2009.06.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Revised: 06/01/2009] [Accepted: 06/02/2009] [Indexed: 10/20/2022]
Abstract
Primary or transmitted antiretroviral drug resistance mutations pose a significant obstacle for optimizing antiviral treatment. When present at low-levels, resistance mutations are less likely to be detected by standard genotyping assays. This study utilizes a novel rolling circle amplification (RCA) method using padlock probes to achieve the sensitive, specific and low-level detection of the NNRTI resistance K103N from 59 HIV+ treatment-naïve patients from Beijing, China. Using standard genotyping methods, primary drug resistance mutations to either protease or RT inhibitors were found in 25% (15/59) of patients attending hospital clinics in Beijing. Among these 15 patients with antiretroviral (ARV) resistance mutations, standard sequence-based genotyping revealed that most (10/15) had the 103N. Using a highly sensitive RCA assay, 5 more patients among the 59 treatment-naïve cohort were found to have the 103N, but at low-levels, leading to an overall rate of 103N at 25.4% (15/59) in this population. The high prevalence of the 103N suggests that baseline resistance testing should be performed before treatment in this population. Importantly, the new RCA technology allows large-scale, sensitive detection of drug resistance mutations, including detection of minority populations with minimal equipment requirement.
Collapse
Affiliation(s)
- Bin Wang
- Center for Virus Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW 2145, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Wang B, Lau KA, Ong LY, Shah M, Steain MC, Foley B, Dwyer DE, Chew CB, Kamarulzaman A, Ng KP, Saksena NK. Complex patterns of the HIV-1 epidemic in Kuala Lumpur, Malaysia: Evidence for expansion of circulating recombinant form CRF33_01B and detection of multiple other recombinants. Virology 2007; 367:288-97. [PMID: 17604072 DOI: 10.1016/j.virol.2007.05.033] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Revised: 05/10/2007] [Accepted: 05/15/2007] [Indexed: 10/23/2022]
Abstract
The HIV protease-reverse transcriptase (PR-RT) (1047 bp), gp120-env (891 bp) and gp41-env (547 bp) regions from the plasma of 115 HIV-1-infected patients in Kuala Lumpur (KL), Malaysia were sequenced. Detailed phylogenetic and bootscanning analyses were performed to determine the mosaic structure of the HIV-1 strains and their recombination breakpoint(s). Among the 50 patient samples in which all three regions could be amplified, the HIV-1 CRF01_AE subtype (46%) was predominant followed by subtypes B (10%) and B' (6%). A total of 9/50 (18%) patients were infected with a CRF01_AE/B inter-subtype recombinant, displaying a recombinant form (RF)(PR-RT), CRF01_AE(gp120-env) and CRF01_AE(gp41-env). This RF was derived from the Thai variants of CRF01_AE and B' subtype, with two distinct B' subtype segments in the backbone of CRF01_AE, similar to the newly identified CRF33_01B. In addition, one sample demonstrated a close structural relationship with the new CRF33_01B in the PR-RT region but displayed B' segment in part of the env region (RF(PR-RT), CRF01_AE/B'(gp120-env) and B'(gp41-env)) indicating continuing evolution of CRF33_01B. The remaining 18% of samples were identified as unique recombinant forms (URFs).
Collapse
Affiliation(s)
- Bin Wang
- Retroviral Genetics Division, Center for Virus Research, Westmead Millennium Institute, Westmead Hospital, The University of Sydney, Westmead NSW, Sydney, Australia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|